Free Trial
NASDAQ:HALO

Halozyme Therapeutics (HALO) Stock Price, News & Analysis

$44.97
+0.26 (+0.58%)
(As of 05/20/2024 ET)
Today's Range
$44.30
$45.07
50-Day Range
$37.81
$45.82
52-Week Range
$31.86
$46.16
Volume
656,825 shs
Average Volume
1.21 million shs
Market Capitalization
$5.72 billion
P/E Ratio
18.58
Dividend Yield
N/A
Price Target
$53.14

Halozyme Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
18.2% Upside
$53.14 Price Target
Short Interest
Bearish
6.69% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.12
Upright™ Environmental Score
News Sentiment
1.28mentions of Halozyme Therapeutics in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$1.20 M Sold Last Quarter
Proj. Earnings Growth
22.67%
From $3.44 to $4.22 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.73 out of 5 stars

Medical Sector

61st out of 918 stocks

Biological Products, Except Diagnostic Industry

6th out of 146 stocks

HALO stock logo

About Halozyme Therapeutics Stock (NASDAQ:HALO)

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

HALO Stock Price History

HALO Stock News Headlines

The 3 Best Biotech Stocks to Buy in May 2024
The Trade Desk: Q1 Earnings Snapshot
Q1 2024 Halozyme Therapeutics Inc Earnings Call
Halozyme Therapeutics: Q1 Earnings Snapshot
How Novo-Catalent Deal Affects Halozyme (HALO)?
Crossject reports audited financial results for 2023
9 Analysts Have This To Say About Halozyme Therapeutics
See More Headlines
Receive HALO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Halozyme Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/20/2024
Today
5/20/2024
Next Earnings (Estimated)
8/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:HALO
CUSIP
40637H10
Employees
373
Year Founded
1998

Price Target and Rating

Average Stock Price Target
$53.14
High Stock Price Target
$71.00
Low Stock Price Target
$40.00
Potential Upside/Downside
+18.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
6 Analysts

Profitability

Net Income
$281.59 million
Pretax Margin
45.44%

Debt

Sales & Book Value

Annual Sales
$829.25 million
Cash Flow
$3.20 per share
Book Value
$0.63 per share

Miscellaneous

Free Float
123,838,000
Market Cap
$5.72 billion
Optionable
Optionable
Beta
1.26

Social Links

5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Helen I. Torley M.B. Ch. B. (Age 61)
    M.R.C.P., President, CEO & Director
    Comp: $1.82M
  • Ms. Nicole LaBrosseMs. Nicole LaBrosse (Age 41)
    Senior VP & CFO
    Comp: $849.36k
  • Dr. Michael J. LaBarre Ph.D. (Age 60)
    Senior VP & Chief Technical Officer
    Comp: $843.89k
  • Mr. Mark Snyder Esq.
    Senior VP & Chief Legal Officer
  • Ms. Cortney Caudill M.B.A.
    Chief Operations Officer
  • Ms. Tram Bui
    Head of Investor Relations & Corporate Communications
  • Ms. Amy Marinne Fox
    Senior Vice President of Human Resources
  • Ms. Kristin Schwartzbauer
    Head of Quality
  • Mr. Gary Grote
    Chief Commercial Officer
  • Dr. Christopher Wahl M.B.A.
    M.D., Chief Business Officer

HALO Stock Analysis - Frequently Asked Questions

Should I buy or sell Halozyme Therapeutics stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Halozyme Therapeutics in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" HALO shares.
View HALO analyst ratings
or view top-rated stocks.

What is Halozyme Therapeutics' stock price target for 2024?

6 equities research analysts have issued twelve-month price objectives for Halozyme Therapeutics' shares. Their HALO share price targets range from $40.00 to $71.00. On average, they expect the company's share price to reach $53.14 in the next twelve months. This suggests a possible upside of 18.2% from the stock's current price.
View analysts price targets for HALO
or view top-rated stocks among Wall Street analysts.

How have HALO shares performed in 2024?

Halozyme Therapeutics' stock was trading at $36.96 at the beginning of the year. Since then, HALO shares have increased by 21.7% and is now trading at $44.97.
View the best growth stocks for 2024 here
.

When is Halozyme Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024.
View our HALO earnings forecast
.

How were Halozyme Therapeutics' earnings last quarter?

Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced its earnings results on Tuesday, November, 2nd. The biopharmaceutical company reported $1.48 earnings per share for the quarter, beating analysts' consensus estimates of $0.42 by $1.06. The biopharmaceutical company earned $115.83 million during the quarter, compared to the consensus estimate of $101.94 million. Halozyme Therapeutics had a trailing twelve-month return on equity of 225.71% and a net margin of 36.94%. During the same quarter in the previous year, the company earned $0.25 earnings per share.

What guidance has Halozyme Therapeutics issued on next quarter's earnings?

Halozyme Therapeutics updated its FY 2024 earnings guidance on Wednesday, May, 8th. The company provided earnings per share guidance of 3.550-3.900 for the period, compared to the consensus estimate of 3.680. The company issued revenue guidance of $915.0 million-$985.0 million, compared to the consensus revenue estimate of $951.5 million.

What is Helen Torley's approval rating as Halozyme Therapeutics' CEO?

12 employees have rated Halozyme Therapeutics Chief Executive Officer Helen Torley on Glassdoor.com. Helen Torley has an approval rating of 75% among the company's employees.

What other stocks do shareholders of Halozyme Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Halozyme Therapeutics investors own include Xtrackers California Municipal Bond ETF (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Micron Technology (MU), Gilead Sciences (GILD), Athabasca Oil (ATH), NIC (EGOV), Allergan (AGN) and AbbVie (ABBV).

Who are Halozyme Therapeutics' major shareholders?

Halozyme Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (10.27%), TD Asset Management Inc (2.00%), Epoch Investment Partners Inc. (1.13%), Price T Rowe Associates Inc. MD (1.02%), Allspring Global Investments Holdings LLC (0.55%) and Allspring Global Investments Holdings LLC (0.55%). Insiders that own company stock include Connie Matsui, Helen Torley, James M Daly, Jean-Pierre Bizzari, Jeffrey William Henderson, Matthew L Posard, Michael J Labarre and Nicole Labrosse.
View institutional ownership trends
.

How do I buy shares of Halozyme Therapeutics?

Shares of HALO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Halozyme Therapeutics have any subsidiaries?
The following companies are subsidiares of Halozyme Therapeutics: Halozyme Holdings Ltd., Halozyme Inc., Halozyme Switzerland GmbH, and Halozyme Switzerland Holdings GmbH.
Read More
This page (NASDAQ:HALO) was last updated on 5/21/2024 by MarketBeat.com Staff

From Our Partners